Yutaro Kato

Prof. Yutaro Kato

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HMHiroshi Matsuoka
Hiroshi Matsuoka
ZMZenichi Morise
Zenichi Morise
CTChihiro Tanaka
Chihiro Tanaka
THTakahiro Hayashi
Takahiro Hayashi
YIYoshiaki Ikeda
Yoshiaki Ikeda
IUIchiro Uyama
Ichiro Uyama
Although hepatectomy for metastatic colorectal cancer (mCRC) prolongs survival in up to 40% of people, recurrence rates approach 70%. We used a multidisciplinary approach to treat recurrent liver metastases, including chemotherapy, surgery, and palliative care. On the other hand, development of chemotherapeutic agents is remarkable and improves long-term survival. However, whether chemotherapy and repeat hepatectomy combination therapy improve survival or not is still unclear. The aim of this study was to analyze the outcomes of repeat hepatectomy with systemic chemotherapy for mCRC. Following Institutional Review Board approval, we reviewed the records of all patients who underwent hepatectomy for mCRC between 1974 and 2015 at Fujita Health University Hospital. We used the Kaplan–Meier method to estimate overall survival from the first and last hepatectomy in multi hepatectomy cases after 2005 and compared outcomes between groups using the log-rank test. A total of 426 liver resections were performed for mCRC; of these, 236 cases were performed after 2005 (late group). In 118 (50%) cases, the site of recurrence was the liver, 59 (50%) underwent repeat hepatectomy, and 14 cases had ≥ 2 repeat hepatectomies. Overall survival (OS) before and after 2005 was 42.2 and 64.1 months, respectively, with the late group having better OS compared to the early (1974–2004) group. OS for single hepatectomy cases was 83.2 months, for two hepatectomies was 42.9 months, and for three hepatectomies was 35.3 months. In total, 59 patients did not undergo surgery after recurrence with an OS of 28.7 months. Mortality of the second and third repeat hepatectomy was 1.7% and 15.3%, respectively. Repeat hepatectomy with systemic chemotherapy for mCRC is feasible and might achieve improved survival in carefully selected patients.

11 July 2022 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
YKYutaro Kato
Yutaro Kato
ASAtsushi Sugioka
Atsushi Sugioka
MKMasayuki Kojima
Masayuki Kojima
GKGozo Kiguchi
Gozo Kiguchi
SMSatoshi Mii
Satoshi Mii
IUIchiro Uyama
Ichiro Uyama

9 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YKYutaro Kato
Yutaro Kato
Atsushi SugiokaAtsushi Sugioka
Atsushi Sugioka
MKMasayuki Kojima
Masayuki Kojima
SMSatoshi Mii
Satoshi Mii
YUYuichiro Uchida
Yuichiro Uchida
IUIchiro Uyama
Ichiro Uyama
Surgical techniques and outcomes of minimally invasive anatomic liver resection (AR) using the extrahepatic Glissonian approach for hepatocellular carcinoma (HCC) are undefined. In 327 HCC cases undergoing 185 open (OAR) and 142 minimally invasive (MIAR; 102 laparoscopic and 40 robotic) ARs, perioperative and long-term outcomes were compared between the approaches, using propensity score matching. After matching (91:91), compared to OAR, MIAR was significantly associated with longer operative time (643 vs. 579 min, p = 0.028); less blood loss (274 vs. 955 g, p < 0.0001); a lower transfusion rate (17.6% vs. 47.3%, p < 0.0001); lower rates of major 90-day morbidity (4.4% vs. 20.9%, p = 0.0008), bile leak or collection (1.1% vs. 11.0%, p = 0.005), and 90-day mortality (0% vs. 4.4%, p = 0.043); and shorter hospital stay (15 vs. 29 days, p < 0.0001). On the other hand, laparoscopic and robotic AR cohorts after matching (31:31) had comparable perioperative outcomes. Overall and recurrence-free survivals after AR for newly developed HCC were comparable between OAR and MIAR, with potentially improved survivals in MIAR. The survivals were comparable between laparoscopic and robotic AR. MIAR was technically standardized using the extrahepatic Glissonian approach. MIAR was safe, feasible, and oncologically acceptable and would be the first choice of AR in selected HCC patients.

28 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TKTeiji Kuzuya
Teiji Kuzuya
NKNaoto Kawabe
Naoto Kawabe
MAMizuki Ariga
Mizuki Ariga
EOEizaburo Ohno
Eizaburo Ohno
KFKohei Funasaka
Kohei Funasaka
YHYoshiki Hirooka
Yoshiki Hirooka
(1) Background: This study aimed to investigate clinical outcomes for cabozantinib in clinical practice in patients with advanced hepatocellular carcinoma (HCC) previously treated with atezolizumab plus bevacizumab (Atz/Bev), with a focus on whether patients met criteria of Child–Pugh Class A and Eastern Cooperative Oncology Group performance status (ECOG-PS) score 0/1 at baseline. (2) Methods: Eleven patients (57.9%) met the criteria of both Child–Pugh class A and ECOG-PS score 0/1 (CP-A+PS-0/1 group) and eight patients (42.1%) did not (Non-CP-A+PS-0/1 group); efficacy and safety were retrospectively evaluated. (3) Results: Disease control rate was significantly higher in the CP-A+PS-0/1 group (81.1%) than in the non-CP-A+PS-0/1 group (12.5%). Median progression-free survival, overall survival and duration of cabozantinib treatment were significantly longer in the CP-A+PS-0/1 group (3.9 months, 13.4 months, and 8.3 months, respectively) than in the Non-CP-A+PS-0/1 group (1.2 months, 1.7 months, and 0.8 months, respectively). Median daily dose of cabozantinib was significantly higher in the CP-A+PS-0/1 group (22.9 mg/day) than in the non-CP-A+PS-0/1 group (16.9 mg/day). (4) Conclusions: Cabozantinib in patients previously treated with Atz/Bev has potential therapeutic efficacy and safety if patients have good liver function (Child–Pugh A) and are in good general condition (ECOG-PS 0/1).

25 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMArimasa Miyama
Arimasa Miyama
ZMZenichi Morise
Zenichi Morise
Luca Antonio M. AldrighettiLuca Antonio M. Aldrighetti
Luca Antonio M. Aldrighetti
GBGiulio Belli
Giulio Belli
Francesca RattiFrancesca Ratti
Francesca Ratti
GWGo Wakabayashi
Go Wakabayashi
Less morbidity is considered among the advantages of laparoscopic liver resection (LLR) for HCC patients. However, our previous international, multi-institutional, propensity score-based study of emerging laparoscopic repeat liver resection (LRLR) failed to prove this advantage. We hypothesize that these results may be since the study included complex LRLR cases performed during the procedure’s developing stage. To examine it, subgroup analysis based on propensity score were performed, defining the proximity of the tumors to major vessels as the indicator of complex cases. Among 1582 LRLR cases from 42 international high-volume liver surgery centers, 620 cases without the proximity to major vessels (more than 1 cm far from both first–second branches of Glissonian pedicles and major hepatic veins) were selected for this subgroup analysis. A propensity score matching (PSM) analysis was performed based on their patient characteristics, preoperative liver function, tumor characteristics and surgical procedures. One hundred and fifteen of each patient groups of LRLR and open repeat liver resection (ORLR) were earned, and the outcomes were compared. Backgrounds were well-balanced between LRLR and ORLR groups after matching. With comparable operation time and long-term outcome, less blood loss (283.3±823.0 vs. 603.5±664.9 mL, p = 0.001) and less morbidity (8.7 vs. 18.3 %, p = 0.034) were shown in LRLR group than ORLR. Even in its worldwide developing stage, LRLR for HCC patients could be beneficial in blood loss and morbidity for the patients with less complexity in surgery.

3 June 2023 in Surgery
Verified
Journal Article
Closed access
GBGiammauro Berardi
Giammauro Berardi
TKT. Peter Kingham
T. Peter Kingham
WZWanguang Zhang
Wanguang Zhang
NSNicholas L. Syn
Nicholas L. Syn
YKYe-Xin Koh
Ye-Xin Koh
AMAlessandro Mazzotta
Alessandro Mazzotta